Talphera’s (TLPH) “Buy” Rating Reiterated at HC Wainwright

Talphera (NASDAQ:TLPH)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 275.00% from the company’s previous close.

Several other research firms have also commented on TLPH. Westpark Capital started coverage on shares of Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Talphera presently has an average rating of “Hold” and an average price target of $3.00.

Talphera Stock Performance

TLPH stock opened at $0.80 on Friday. The firm has a market cap of $41.52 million, a PE ratio of -2.58 and a beta of 0.76. The firm’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.95. Talphera has a one year low of $0.38 and a one year high of $1.57.

Talphera (NASDAQ:TLPH) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03.

Insider Activity at Talphera

In other Talphera news, CEO Vincent J. Angotti purchased 213,310 shares of the company’s stock in a transaction on Friday, March 13th. The stock was acquired at an average price of $0.59 per share, for a total transaction of $125,852.90. Following the completion of the purchase, the chief executive officer directly owned 800,705 shares in the company, valued at approximately $472,415.95. The trade was a 36.31% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Talphera

Several institutional investors have recently modified their holdings of the business. Group One Trading LLC grew its stake in shares of Talphera by 3,224.0% in the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares in the last quarter. Virtu Financial LLC purchased a new stake in Talphera in the third quarter valued at $29,000. Mariner LLC lifted its position in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after acquiring an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Talphera in the fourth quarter valued at $42,000. Finally, Dauntless Investment Group LLC purchased a new stake in Talphera in the third quarter valued at $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.